Celecoxib & Warfarin Interaction

Celecoxib, a selective COX-2 inhibitor, increases bleeding risk when combined with warfarin, though through a somewhat different mechanism than non-selective NSAIDs like ibuprofen ^[1]. While celecoxib was developed to provide anti-inflammatory benefit with reduced gastrointestinal toxicity, it still carries meaningful bleeding risk when combined with anticoagulants ^[2]. Celecoxib can increase INR by inhibiting CYP2C9, the primary enzyme responsible for warfarin metabolism, leading to elevated warfarin plasma concentrations and enhanced anticoagulant effect ^[1][3]. Although celecoxib has less impact on platelet function than non-selective NSAIDs (because it spares COX-1 at therapeutic doses), this perceived safety advantage is partially offset by the pharmacokinetic interaction that raises warfarin levels ^[3]. The FDA labeling for both celecoxib and warfarin includes warnings about this combination ^[1][4].

The celecoxib-warfarin interaction involves both pharmacokinetic and pharmacodynamic components. Pharmacokinetically, celecoxib is a moderate inhibitor of CYP2C9, the same enzyme responsible for metabolizing the more potent S-enantiomer of warfarin ^[3]. By inhibiting CYP2C9, celecoxib reduces the clearance of S-warfarin, which is 3–5 times more potent than R-warfarin in producing anticoagulation ^[3]. This results in elevated S-warfarin concentrations and a clinically significant increase in INR ^[3]. Pharmacodynamically, while celecoxib selectively inhibits COX-2 at therapeutic doses and largely spares COX-1-dependent platelet thromboxane production, some COX-1 inhibition may occur at higher doses ^[2]. Additionally, COX-2 inhibition reduces vascular prostacyclin production, which has antiplatelet and vasodilatory properties, potentially creating a prothrombotic state that paradoxically coexists with increased bleeding from elevated INR ^[4]. Celecoxib also reduces renal prostaglandin synthesis, which can cause fluid retention and affect hemodynamics ^[2].

Clinical studies have demonstrated that celecoxib increases INR by approximately 10–15% in warfarin-treated patients, though individual responses vary considerably ^[3]. A randomized controlled trial found that celecoxib 200 mg twice daily increased the mean INR by approximately 0.4 units in patients on stable warfarin therapy, with some patients experiencing INR increases sufficient to exceed the therapeutic range ^[3]. While celecoxib causes less GI mucosal damage than non-selective NSAIDs (approximately 50% fewer endoscopic ulcers in the CLASS trial), the combination with warfarin still increases the overall bleeding risk significantly compared to warfarin alone ^[2]. Post-marketing surveillance data have identified cases of serious bleeding events, including GI hemorrhage and intracranial bleeding, in patients receiving celecoxib with warfarin ^[1]. The risk is highest in elderly patients, those with prior GI bleeding, and those with labile INR control ^[4].

If celecoxib is prescribed to a warfarin-treated patient, start with the lowest effective dose (100 mg twice daily or 200 mg once daily) for the shortest possible duration ^[1]. Check INR within 3–5 days of starting celecoxib, as the CYP2C9 inhibition will begin to elevate warfarin levels ^[3]. Preemptively reduce the warfarin dose by 5–10% if baseline INR is at the upper end of the target range ^[4]. Add a proton pump inhibitor for gastroprotection, even though celecoxib has a better GI safety profile than non-selective NSAIDs, because the elevated INR from the interaction increases bleeding risk from any GI lesion ^[2]. Educate patients about bleeding signs and the importance of adherence to INR monitoring ^[1]. When celecoxib is discontinued, recheck INR within 3–5 days, as warfarin levels will decrease and the dose may need to be readjusted upward ^[3].

Check INR at baseline, then 3–5 days after starting celecoxib, weekly during the first month, and with any celecoxib dose changes ^[1]. Monitor INR after celecoxib discontinuation as well, since removal of CYP2C9 inhibition will alter warfarin metabolism ^[3]. Assess for bleeding symptoms at each encounter: bruising, bleeding gums, blood in urine or stool, nosebleeds, hemoptysis ^[1]. Monitor renal function (celecoxib can reduce renal blood flow) and blood pressure (COX-2 inhibitors can cause fluid retention and hypertension) ^[2]. Check hemoglobin if there is any suspicion of occult bleeding ^[4]. Evaluate for cardiovascular risk, as COX-2 inhibitors have been associated with increased cardiovascular events in some studies, an important consideration in patients already on warfarin for thromboembolic conditions ^[4].

Acetaminophen (up to 2g/day) remains the safest analgesic for warfarin-treated patients and should be considered first-line ^[1]. Topical anti-inflammatory agents (diclofenac gel, topical menthol preparations) provide localized relief without systemic interaction ^[2]. For inflammatory arthritis, optimizing disease-modifying therapy (methotrexate, hydroxychloroquine, biologics) reduces reliance on NSAIDs ^[4]. If systemic anti-inflammatory therapy is essential and celecoxib is not tolerable, short courses of low-dose prednisone may be considered, though corticosteroids have their own interaction with warfarin ^[4]. Physical therapy, joint supports, and non-pharmacologic pain management should be part of the treatment plan ^[1]. For some patients, switching from warfarin to a direct oral anticoagulant (DOAC) may simplify management, though DOAC-NSAID combinations still carry increased bleeding risk ^[4].